scholarly journals Oxidative Stress Induction By Pesticides May Cause Lung Cancer Incidence

2022 ◽  
Author(s):  
Gholamreza Asadikaram ◽  
Hossein Pourghdamyari ◽  
Moslem Abolhassani ◽  
Mojtaba Abbasi-Jorjandi ◽  
Sanaz Faramarz ◽  
...  
Keyword(s):  
Oxidative Stress ◽  
Lung Cancer ◽  
Cancer Patients ◽  
Cancer Incidence ◽  
Organophosphorus Pesticides ◽  
Paraoxonase 1 ◽  
Lung Cancer Incidence ◽  
Lung Cancer Patients ◽  
Enzymatic Antioxidant ◽  
Control Subjects

Abstract Background and aims: Pesticides are nowadays known as one of the most important causes of human disorders worldwide. The aim of the present study was to investigate the role of organochlorine pesticides (OCPs) and organophosphorus pesticides (OPPs) in the development of lung cancer. Methods We determined the levels of seven derived OCP residues (α-HCH, β-HCH, γ-HCH, 2,4 DDT, 4,4 DDT, 2,4 DDE, and 4,4 DDE) and enzymatic antioxidant biomarkers including paraoxonase-1 (PON-1), erythrocyte's acetylcholinesterase (AChE), glutathione peroxidase (GPx), superoxide dismutase (SOD), catalase (CAT), and non-enzymatic antioxidant biomarkers including total antioxidant capacity (TAC), protein carbonyl (PC), malondialdehyde (MDA), and nitric oxide (NO) in the blood samples of 51 lung cancer patients and 51 healthy subjects as controls. Furthermore, the effects of OPP exposure on the development of lung cancer and oxidative stress (OS) are indirectly assessed by measuring AChE and PON-1 enzyme activities. Results The average values of all the measured OCPs were significantly higher in lung cancer patients when compared with healthy control subjects. AChE, PON-1, GPx, and CAT activity levels as well as the amounts of PC, MDA, and NO were higher in patients with lung cancer than in the control subjects, while TAC values were lower in the patients. Moreover, our data showed a significant association between OCP concentrations and OS parameters. Conclusion The results suggest that OCPs and OPPs may have a role in lung cancer incidence in southeastern Iran, and at least one of the mechanisms by which OCPs and OPPs may contribute to increasing the development of lung cancer in the studied area is through OS generation.

Five vitamin D receptor polymorphisms (FokI, BsmI, Apa1, Taq1, and Cdx2) and lung cancer risk.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. e12013-e12013
Author(s):  
Rong Li ◽  
Ming Tian ◽  
Meili Ma ◽  
Jun Pei ◽  
Yiyi Song ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Vitamin D ◽  
Cancer Patients ◽  
Cancer Incidence ◽  
Smoking Status ◽  
Chinese Patients ◽  
Healthy Controls ◽  
Lung Cancer Incidence ◽  
Lung Cancer Patients ◽  
Incidence And Mortality

e12013 Background: Vitamin D and its receptor (VDR) have been implicated in lung cancer incidence and mortality. Here we assess the relationships between VDR single nucleotide polymorphisms (SNPs) (FokI, BsmI, ApaI, Taq, Cdx2) and lung cancer incidence in Chinese patients. Methods: Genomic DNA was extracted from peripheral blood samples. Five VDR SNPs (FokI, BsmI, ApaI, Taq, Cdx2) were detected by polymerase chain reaction. Genotype analysis was conducted using mass spectrograph. Results: A total of 67 lung cancer patients and 72 healthy controls participated in the study. There were more males and current smokers among the lung cancer patients than among healthy controls. Lung cancer patients were much older than controls. Age and smoking status were included in the equation for predicting disease status. The CC-AA (Apa1-Cdx2) and the CC-AA-CC (ApaI-Cdx2- FokI) haplotypes were associated with higher lung cancer incidence. The rs1544410 (BsmI) and rs731236 (TaqI) were not associated with higher lung cancer incidence, but they were associated with rs797523 (ApaI). Conclusions: There is a significant correlation between certain VDR SNPs (FokI, ApaI, Cdx2) and lung cancer incidence in Chinese people.

scholarly journals Sequencing and structure analysis of UBC gene for breast and ‎lung cancer

2019 ◽  
Vol 10 (3) ◽  
pp. 1640-1645
Author(s):  
Saleen Salam Abdulhadi ◽  
Abbas Abdullah Mohammed‎
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Genetic Alterations ◽  
Cancer Disease ◽  
Blood Samples ◽  
Lung Cancer Patients ◽  
Control Subjects ◽  
Exon 1 ◽  
Healthy Control ◽  
Transition Mutation

In the present study, sequencing approach has been adopted for exploring the ‎genetic alteration of sequences for the ubiquitin gene (UBC) in patients of breast and ‎lung cancer and comparing the results with a normal sequence that obtained from NCBI. ‎The aim of this study was to detect for genetic alterations of UBC gene in the breast and ‎lung cancer patients then compare with healthy control subjects, to investigate the ‎association between the mutations at the intron region of the UBC gene and cancer disease, ‎‎40 blood samples were examined from patients with breast and lung cancer aged ranged from (17-65) years, were collected at Al-Amal Hospital of cancer in Baghdad ‎province/Iraq, the period of collecting samples were from October/2018 to January/2019. ‎While twenty-two blood samples from healthy control subjects were collected at ages ‎ranged from(19-59). After DNA extraction, the PCR primer was designed to amplify the ‎region in the UBC gene (part of exon 1 and the whole intron). Here we report the polymorphism of the intron sequence of the UBC gene in Iraqi population as the results of sequencing the PCR amplified products showed three different transition mutation G→A, ‎C→T, T→C in patients with breast cancer were also appeared in healthy control subjects. While nine transition mutations appeared in lung cancer patients, at different locations ‎of the sequence were detected by BLAST tool. ‎

Significance of the urinary 8-OHdG level as an oxidative stress marker in lung cancer patients

Lung Cancer ◽  
2009 ◽  
Vol 63 (1) ◽  
pp. 111-114 ◽  
Author(s):  
Tokujiro Yano ◽  
Fumihiro Shoji ◽  
Hiromitsu Baba ◽  
Tadashi Koga ◽  
Takeshi Shiraishi ◽  
...  
Keyword(s):  
Oxidative Stress ◽  
Lung Cancer ◽  
Cancer Patients ◽  
Oxidative Stress Marker ◽  
Lung Cancer Patients ◽  
Stress Marker

scholarly journals Nitric Oxide in Occurrence, Progress and Therapy of Lung Cancer: A Systemic Review and Meta-analysis

2021 ◽  
Author(s):  
Hongbin Zhou ◽  
Zhewen Chen ◽  
Ying Chen ◽  
Jiuke Li ◽  
Sa Ye
Keyword(s):  
Nitric Oxide ◽  
Lung Cancer ◽  
Cancer Patients ◽  
Meta Analysis ◽  
Lung Cancer Patients ◽  
Time Points ◽  
Control Subjects ◽  
Significant Difference ◽  
Different Populations ◽  
Nsclc Patients

Abstract Background: Nitric oxide (NO) plays an important role in lung cancer. However, the results of previous studies about NO in the occurrence, progress and therapy were not consistent. Therefore, we conducted a meta-analysis to evaluate the relationship between NO and lung cancer.Method: We carried out comprehensive search in the databases, and collected related studies. The data of fraction of exhaled nitric oxide (FeNO) or blood NO in different populations (lung cancer patients and control subjects) and different time points (before therapy and after therapy) were extracted by two investigators. A random effect model was applied to analyze the differences of FeNO and blood NO in different populations and different time points. To further compare NO level of each subgroup with different pathological types and different stages, a network meta-analysis (NMA) was performed.Results: 50 studies including 2551 cases and 1691 controls were adopted in this meta-analysis. The FeNO (SMD 3.01, 95% CI 1.89-4.13, p < 0.00001) and blood NO (SMD 1.34, 95% CI 0.84-1.85, p < 0.00001) level in lung cancer patients was much higher than that in control subjects. NMA model indicated blood NO level in each cancer type except SCLC was higher than that in control patients. There was no significant difference of blood NO level among four kinds of lung cancer patients. Blood NO level in LCC patients (SUCRA=83.5%) was the highest. Blood NO level in advanced stage but not early stage was higher than that in control subjects. Patients in advanced stage (SUCRA=95.5%) had the highest blood NO level. No significant difference of FeNO (SMD -0.04, 95% CI -0.46-0.38, p > 0.05) and blood NO level (SMD -0.36, 95% CI -1.08-0.36, p > 0.05) was observed between pretreatment and posttreatment in all patients. However, FeNO level elevated (SMD 0.28, 95% CI 0.04-0.51, p = 0.02) and blood NO level decreased in NSCLC patients (SMD -0.95, 95% CI -1.89-0.00, p = 0.05) after therapy. Conclusion: FeNO and blood NO level would contribute to diagnosis of lung cancer and evaluation of therapy effect, especially for NSCLC patients.

scholarly journals The effect of anti-cancer and anti-tuberculosis treatments in lung cancer patients with active tuberculosis: a retrospective analysis

2020 ◽  
Author(s):  
MEI CHAI ◽  
Qingming Shi
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Side Effect ◽  
Treatment Completion ◽  
Completion Rate ◽  
Karnofsky Performance Score ◽  
Lung Cancer Patients ◽  
Control Subjects ◽  
Tb Treatment ◽  
Anti Cancer

Abstract Background Lung tuberculosis (TB) and lung cancer have a complex relationship. Data concerning TB treatment in lung cancer patients are still incomplete. The aim of this study was to investigate the effects of anti-cancer and anti-tuberculosis treatments in lung cancer patients with active lung TB. Methods In a retrospective cohort study, lung cancer patients with active lung TB were identified between January 2013 and December 2016. Age- and sex-matched lung cancer patients without tuberculosis were selected as control subjects. Anti-cancer and anti-tuberculosis treatments were administered according to the national guidelines. The clinical courses and responses of lung cancer patients with and without active lung TB were examined and compared.Results A total of 31 consecutive lung cancer patients were diagnosed with active lung TB. Fifty-one lung cancer patients without TB were enrolled as control subjects. Most patients in the two groups were elderly, had advanced non-small cell lung cancer and had tumor burdens. The anti-cancer treatment completion rate and response rate were not different between two group (87.1% in TB treatment patients vs. 92.2% in lung cancer patients; 77.4% in TB treatment patients vs. 88.2% in lung cancer patients, respectively). The anti-tuberculosis treatment completion rate and success rate was 87.1% and 80.7%. The median survival times were not different between two groups (52 weeks in TB treatment patients vs. 57 weeks in lung cancer patients). The change in Karnofsky performance score was also not different between two groups. The most common side effect in TB treatment patients was liver injury (61.3%). The most serious side effect in TB treatment patients was leukocyte deficiency (9.7% in Grade 3). Both of side effects mentioned above were not different between two groups. Conclusion Both anti-cancer and anti-tuberculosis treatments can be safely and effectively administered in lung cancer patients with active lung TB. Attention should be paid to the risk of tuberculosis in lung cancer patients in TB high-burden countries.

scholarly journals Treatment outcomes of tuberculosis in patients with lung cancer: a retrospective analysis

2019 ◽  
Author(s):  
MEI CHAI ◽  
Qingming Shi
Keyword(s):  
Lung Cancer ◽  
Treatment Group ◽  
Cancer Patients ◽  
Control Group ◽  
Chemotherapy Response ◽  
Survival Times ◽  
Lung Cancer Patients ◽  
Control Subjects ◽  
Tb Treatment ◽  
Lung Tuberculosis

Abstract Background Lung tuberculosis (TB) and cancer have a complex relationship. Data concerning TB treatment in lung cancer patients are still incomplete. The aim of this study was to investigate the clinical characteristics and treatment responses of lung tuberculosis in lung cancer patients. Methods In a retrospective cohort study, lung cancer patients with tuberculosis were identified between January 2013 and December 2016. These patients were divided into a TB treatment group and a TB nontreatment group. Age- and sex-matched lung cancer patients without tuberculosis were selected as control subjects. The clinical courses and responses of patients with and without tuberculosis were examined and compared. Results A total of 98 consecutive lung cancer patients were diagnosed with lung tuberculosis (47 patients in the TB treatment group and 51 patients in the TB nontreatment group). Fifty-one lung cancer patients without TB were enrolled as control subjects. Most patients in the three groups were elderly, had advanced non-small cell lung cancer and had tumor burdens. Compared with patients in the TB nontreatment group, the patients in the TB treatment group had more active TB (66% vs. 5.9%, p < 0.001) and were newly diagnosed (55.3% vs. 23.5%, p < 0.001). The anti-cancer chemotherapy response rate in the TB nontreatment group was not different from that in the TB treatment group (58.8% vs. 76.6%, p = 0.061), but it was significantly lower than that in the lung cancer group (58.8% vs. 88.2%, p < 0.001). The median survival times of patients in the TB treatment group, TB nontreatment group and cancer patients (control group) were not different (56, 55 and 58 weeks, respectively). No significant differences in serious side effects of chemotherapy were observed among the three groups. Conclusion Both anticancer and antituberculosis treatments can be safely and effectively administered in lung cancer patients with tuberculosis. Attention should be paid to the risk of tuberculosis in lung cancer patients in tuberculosis high-burden countries.

scholarly journals The effect of anti-cancer and anti-tuberculosis treatments in lung cancer patients with active tuberculosis: a retrospective analysis

2020 ◽  
Author(s):  
Mei Chai (Former Corresponding Author) ◽  
Qingming Shi(New Corresponding Author)
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Side Effect ◽  
Treatment Completion ◽  
Completion Rate ◽  
Karnofsky Performance Score ◽  
Lung Cancer Patients ◽  
Control Subjects ◽  
Tb Treatment ◽  
Anti Cancer

Abstract Background Lung tuberculosis (TB) and lung cancer have a complex relationship. Data concerning TB treatment in lung cancer patients are still incomplete. The aim of this study was to investigate the effects of anti-cancer and anti-tuberculosis treatments in lung cancer patients with active lung TB. Methods In a retrospective cohort study, lung cancer patients with active lung TB were identified between January 2013 and December 2016. Age- and sex-matched lung cancer patients without tuberculosis were selected as control subjects. Anti-cancer and anti-tuberculosis treatments were administered according to the national guidelines. The clinical courses and responses of lung cancer patients with and without active lung TB were examined and compared. Results A total of 31 consecutive lung cancer patients were diagnosed with active lung TB. Fifty-one lung cancer patients without TB were enrolled as control subjects. Most patients in the two groups were elderly, had advanced non-small cell lung cancer and had tumor burdens. The anti-cancer treatment completion rate and response rate were not different between two group (87.1% in TB treatment patients vs. 92.2% in lung cancer patients; 77.4% in TB treatment patients vs. 88.2% in lung cancer patients, respectively). The anti-tuberculosis treatment completion rate and success rate was 87.1% and 80.7%. The median survival times were not different between two groups (52 weeks in TB treatment patients vs. 57 weeks in lung cancer patients). The change in Karnofsky performance score was also not different between two groups. The most common side effect in TB treatment patients was liver injury (61.3%). The most serious side effect in TB treatment patients was leukocyte deficiency (9.7% in Grade 3). Both of side effects mentioned above were not different between two groups. Conclusion Both anti-cancer and anti-tuberculosis treatments can be safely and effectively administered in lung cancer patients with active lung TB. Attention should be paid to the risk of tuberculosis in lung cancer patients in TB high-burden countries.

scholarly journals Nitric oxide in occurrence, progress and therapy of lung Cancer: a systemic review and meta-analysis

BMC Cancer ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Hongbin Zhou ◽  
Jiuke Li ◽  
Zhewen Chen ◽  
Ying Chen ◽  
Sa Ye
Keyword(s):  
Nitric Oxide ◽  
Lung Cancer ◽  
Cancer Patients ◽  
Meta Analysis ◽  
Lung Cancer Patients ◽  
Time Points ◽  
Control Subjects ◽  
Significant Difference ◽  
Different Populations ◽  
Nsclc Patients

Abstract Background Nitric oxide (NO) plays an important role in lung cancer. However, the results of previous studies about NO in the occurrence, progress and therapy were not consistent. Therefore, we conducted a meta-analysis to evaluate the relationship between NO and lung cancer. Method We carried out comprehensive search in the databases, and collected related studies. The data of fraction of exhaled nitric oxide (FeNO) or blood NO in different populations (lung cancer patients and control subjects) and different time points (before therapy and after therapy) were extracted by two investigators. A random effect model was applied to analyze the differences of FeNO and blood NO in different populations and different time points. To further compare NO level of each subgroup with different pathological types and different stages, a network meta-analysis (NMA) was performed. Results Fifty studies including 2551 cases and 1691 controls were adopted in this meta-analysis. The FeNO (SMD 3.01, 95% CI 1.89–4.13, p < 0.00001) and blood NO (SMD 1.34, 95% CI 0.84–1.85, p < 0.00001) level in lung cancer patients was much higher than that in control subjects. NMA model indicated blood NO level in each cancer type except SCLC was higher than that in control patients. There was no significant difference of blood NO level among four kinds of lung cancer patients. Blood NO level in LCC patients (SUCRA = 83.5%) was the highest. Blood NO level in advanced stage but not early stage was higher than that in control subjects. Patients in advanced stage (SUCRA = 95.5%) had the highest blood NO level. No significant difference of FeNO (SMD -0.04, 95% CI -0.46-0.38, p > 0.05) and blood NO level (SMD -0.36, 95% CI -1.08-0.36, p > 0.05) was observed between pretreatment and posttreatment in all patients. However, FeNO level elevated (SMD 0.28, 95% CI 0.04–0.51, p = 0.02) and blood NO level decreased in NSCLC patients (SMD -0.95, 95% CI -1.89-0.00, p = 0.05) after therapy. Conclusion FeNO and blood NO level would contribute to diagnosis of lung cancer and evaluation of therapy effect, especially for NSCLC patients.

Evaluation of Oxidative Stress Biomarkers in Brain Metastatic and Non-Metastatic Lung Cancer Patients with Different Cell Types

2021 ◽  
Vol 21 ◽  
Author(s):  
Emre Bilgin ◽  
Gülüzar Atli ◽  
Berna Bozkurt Duman ◽  
Ali I. Okten
Keyword(s):  
Oxidative Stress ◽  
Lung Cancer ◽  
Cancer Patients ◽  
Antioxidant System ◽  
Cell Types ◽  
Oxidative Stress Biomarkers ◽  
Lung Cancer Patients ◽  
Stress Biomarkers ◽  
Metastatic Lung ◽  
Different Cell Types

Background : Oxidative stress lead to an imbalanced prooxidant/antioxidant status can be a critical factor affecting the lung cancer etiopathology. The antioxidant system provides primary protection under oxidative stress. Objective: The purpose of the study was to investigate the serum antioxidant system status in brain metastatic and non-metastatic lung cancer patients with different cell types. Methods: In this prospective study, 33 patients with lung cancer metastasis (metastatic patient group), 36 lung cancer patients (non-metastatic patient group) and 25 healthy control groups were included. Enzymatic (superoxide dismutase, SOD; glutathione peroxidase, GPX; and glutathione reductase, GR) and non-enzymatic (glutathione, GSH) antioxidant system biomarkers with thiobarbituric acid reactive substances (TBARS) levels were studied in the serum samples of the control and patient groups. The oxidative stress biomarkers were measured spectrophotometrically. Results: SOD activity increased though TBARS levels and GR activity decreased in both patient groups compared to the control. GPX activity increased only in the non-metastatic group. Antioxidant biomarkers varied between small cell and non-small cell group patients. GR activity and GSH levels were significantly higher in the non-metastatic group compared to the metastatic group. There were also found correlations between antioxidant parameters in the non-metastatic group. Conclusions: It was emphasized the imbalanced antioxidant system in the duration of the disease related to not only cell type and also the metastatic structure. This is the preliminary study exhibiting the contribution of antioxidant imbalance in different subtypes with varied prognosis and behavior of lung cancer in the presence of brain metastasis. Therefore, oxidative stress biomarkers can serve as a useful tool to get information about the progression of lung cancer. Thus it may provide fundamental data for further cancer researches when considering the diagnosis of the disease.

Sign in / Sign up

Export Citation Format

Share Document